Skip to content
Menu

Abbott Laboratories ABT

Full chart Compare
Set alert

Price alert · ABT

All alert types
103.00 USD -0.87 (-0.84%)

Regular-session close

103.00 0.00 0.00%

After hours · Nov 20, 7:46 PM ET

102.80 Day range 105.50
82.56 52-week range 128.90
YTD
-17.79%
1 year
-16.92%

Fundamental scorecard

16 of 25 checks passed on ABT’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 2 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Value 2 of 5

  • Failed:P/E below its own 5-year median P/E 37.9 against a 5-year median of 33.4.
  • Failed:P/E under 20 P/E 37.9: an earnings yield of 2.6%.
  • Passed:Price to sales below its own 5-year median Price to sales 3.7 against a 5-year median of 4.8.
  • Passed:Price to book below its own 5-year median Price to book 3.5 against a 5-year median of 4.9.
  • Failed:Free cash flow yield above 4% Free cash flow of 6.76B is 3.8% of the market value.

Growth 4 of 5

  • Passed:Revenue grew over the last year Revenue of 48.2B is +10.0% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +5.1% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS 2.69 against 7.97 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years +8.3% a year from FY 2020 to FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +121.5% on the last 12 months.

Profitability 3 of 5

  • Passed:Profitable over the last year Net income of 4.70B over the last 12 months.
  • Passed:Profitable in each of the last five fiscal years A profit in 5 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of 9.1%.
  • Failed:Net margin above its 5-year average Net margin of 9.7% against a 5-year average of 18.6%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 6.76B is 143.7% of net income.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 23.5B against short-term liabilities of 16.2B.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 23.5B against long-term liabilities of 40.5B.
  • Failed:Net debt under 40% of equity Net debt of 26.9B is 52.0% of equity.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 8.86B is 28.4% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 7.6 times the interest expense.

Dividend 4 of 5

  • Passed:Pays a dividend 4.32B paid over the last 12 months.
  • Passed:Yield above 1.5% A yield of 2.4% at the current market value.
  • Failed:Pays out under 75% of profit 92.0% of net income is paid out.
  • Passed:Covered by free cash flow 64.0% of free cash flow is paid out.
  • Passed:Not cut in the last five fiscal years The total paid did not fall in any of the last five fiscal years.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What ABT owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 108B of assets

Debt, equity and cash by year

Now: 26.9B of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

3.31 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

6 / 9 Average

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B3 / 5 overall

  • DCF 4
  • Return on Equity 4
  • Return on Assets 4
  • Debt / Equity 2
  • P/E 1
  • P/B 2

Valuation

P/E 33.5×
P/S 4.9×
P/B 4.2×
P/FCF 29.6×
EV/EBITDA 18.9×
EV/Sales 5.1×
FCF Yield 3.4%

Profitability

Gross Margin 55.5%
Operating Margin 18.2%
Net Margin 14.7%
ROE 12.5%
ROIC 8.4%
ROA 7.5%

Growth (YoY)

Revenue 5.7%
Operating Income 17.9%
EPS (diluted) -51.3%
Free Cash Flow 16.4%

Financial Health

Current Ratio 1.6×
Quick Ratio 1.2×
Debt / Equity 0.3×
Net Debt / EBITDA 0.5×
Interest Coverage 23.6×

Dividends

Dividend Yield 1.9%
Payout Ratio 63.1%

Annual · latest fiscal year ends 2025-12-31